Clinical Trial Detail

NCT ID NCT03519178
Title A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Pfizer

ovary epithelial cancer

Her2-receptor negative breast cancer

triple-receptor negative breast cancer

peritoneum cancer

fallopian tube cancer



Age Groups: adult

Additional content available in CKB BOOST